Literature DB >> 8483401

Stability of time-tradeoff utilities in survivors of myocardial infarction.

J Tsevat1, L Goldman, J R Soukup, G A Lamas, K F Connors, C C Chapin, T H Lee.   

Abstract

To investigate whether time-tradeoff utilities of survivors of myocardial infarction change over time and whether changes in utilities correlate with changes in functional status, the authors conducted serial interviews using a time tradeoff and three measures of functional status in a cohort of 67 patients who had recently had myocardial infarction. The patients were also asked to rate their overall health on a rating scale and were asked about chest pain, exercise status, and employment status. Each patient was interviewed two to five times over one and a half years. The mean (95% CI) time-tradeoff score for all patients was 0.88 (0.84, 0.93). Over a mean interval of 8.4 months, 28 (42%) patients changed Karnofsky scores, 28 (42%) changed Specific Activity Scale classes, and 11 (16%) changed New York Heart Association classes, with most changes representing improvements in functional status. Scores on the rating scale improved by a mean (95% CI) of 0.06 [(0.03, 0.10); p < 0.002], but scores on the time tradeoff remained stable, with a mean (95% CI) change of 0.03 [(-0.02, 0.08); p = NS]. Changes in time-tradeoff scores did not correlate with changes in Specific Activity Scale classes (Kendall's tau = 0.21), New York Heart Association classes (tau = -0.02), or Karnofsky scores (tau = 0.14); with changes on the verbal rating scale (R = 0.20); with changes in chest pain status (tau = -0.05), exercise status (tau = 0.11), or employment status (tau = 0.11); or with interim hospitalizations (tau = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8483401     DOI: 10.1177/0272989X9301300210

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  32 in total

1.  Costs and benefits of free medications after myocardial infarction.

Authors:  Irfan A Dhalla; Monique A Smith; Niteesh K Choudhry; Avram E Denburg
Journal:  Healthc Policy       Date:  2009-11

2.  Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors.

Authors:  Yasuaki Hayashino; Sizuko Nagata-Kobayashi; Takeshi Morimoto; Kenji Maeda; Takuro Shimbo; Tsuguya Fukui
Journal:  J Gen Intern Med       Date:  2004-12       Impact factor: 5.128

3.  Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Authors:  Niteesh K Choudhry; Amanda R Patrick; Elliott M Antman; Jerry Avorn; William H Shrank
Journal:  Circulation       Date:  2008-02-19       Impact factor: 29.690

4.  Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation.

Authors:  Björn Stollenwerk; Afschin Gandjour; Markus Lüngen; Uwe Siebert
Journal:  Eur J Health Econ       Date:  2012-12-30

5.  Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men.

Authors:  Michael Pignone; Stephanie Earnshaw; Cheryl McDade; Mark J Pletcher
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

6.  Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.

Authors:  Thomas S G Sehested; Jenny Bjerre; Seul Ku; Andrew Chang; Alison Jahansouz; Douglas K Owens; Mark A Hlatky; Jeremy D Goldhaber-Fiebert
Journal:  JAMA Cardiol       Date:  2019-02-01       Impact factor: 14.676

7.  Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.

Authors:  Adrian R Levy; Shelagh Szabo; Andrew Briggs; Andreas Pleil; Alison Davie; Gergana Zlateva; Jonathan Javitt
Journal:  J Ophthalmol       Date:  2010-02-16       Impact factor: 1.909

8.  A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention.

Authors:  David Gregory; Dennis J Scotti; Gregory de Lissovoy; Igor Palacios; Simon Dixon; Brijeshwar Maini; William O'Neill
Journal:  Am Health Drug Benefits       Date:  2013-03

Review 9.  Methods and problems in measuring quality of life.

Authors:  D F Cella
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

10.  Aspirin for primary prevention of cardiovascular events.

Authors:  F A Augustovski; S B Cantor; C T Thach; S J Spann
Journal:  J Gen Intern Med       Date:  1998-12       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.